R8404

Rufinamide

≥98% (HPLC), powder

• Synonym(s): 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide
• Empirical Formula (Hill Notation): C₁₀H₈F₂N₄O
• CAS Number: 106308-44-5
• Molecular Weight: 238.19
• MDL number: MFCD00865314
• UNSPSC Code: 12352200
• PubChem Substance ID: 24724595
• NACRES: NA.77

Properties

• Quality Level: 100
• Assay: ≥98% (HPLC)
• form: powder
• color: white
• solubility: DMSO: 9 mg/mL
• originator: Novartis
• storage temp.: −20°C
• SMILES string: NC(=O)c1cn(Cc2c(F)cccc2F)nn1
• InChI: 1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
• InChI key: POGQSBRIGCQNEG-UHFFFAOYSA-N
• Gene Information: human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335)

Description

Application

Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.

Biochem/physiol Actions

Broad-spectrum anticonvulsant.

Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.

Features and Benefits

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Diagnostic Implications

Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.

Safety Information

• Pictograms: GHS08,GHS07
• Signal Word: Warning
• Hazard Statements: H336,H351,H361fd
• Precautionary Statements: P202 - P261 - P271 - P280 - P304 + P340 + P312 - P308 + P313
• Hazard Classifications: Carc. 2 - Repr. 2 - STOT SE 3
• Target Organs: Central nervous system
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable